The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prophylactic cranial irradiation (PCI) in limited-disease small-cell lung cancer (LD-SCLC) patients with brain imaging.
 
Nobuaki Mamesaya
No Relationships to Disclose
 
Kazushige Wakuda
Honoraria - Boehringer Ingelheim; Taiho Pharmaceutical
 
Mie Kotake
No Relationships to Disclose
 
Takumi Fujiwara
No Relationships to Disclose
 
Haruki Kobayashi
No Relationships to Disclose
 
Takahisa Kawamura
No Relationships to Disclose
 
Kazuhisa Nakashima
No Relationships to Disclose
 
Shota Omori
Speakers' Bureau - Chugai Pharma; Ono Pharmaceutical
 
Akira Ono
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Research Funding - Takeda (Inst)
 
Hirotsugu Kenmotsu
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst)
 
Tateaki Naito
Honoraria - Ono Pharmaceutical
 
Haruyasu Murakami
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Teijin Pharma
Consulting or Advisory Role - AstraZeneca; Novartis
Speakers' Bureau - AstraZeneca
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Novartis (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst)
 
Toshiaki Takahashi
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Lilly; Ono Pharmaceutical; Pfizer
Research Funding - AstraZeneca Japan (Inst); Chugai Pharma (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)